The RC Insight Group, a provider of regulatory and clinical consulting services, competitive intelligence and strategic planning for the medical device and biotechnology industry, today announced the appointment of Lori Kahler as President. Kahler will lead the company in the development, promotion and implementation of The RC Insight Group.
(PRWEB) December 23, 2009 -- The RC Insight Group, a provider of regulatory and clinical consulting services, competitive intelligence and strategic planning for the medical device and biotechnology industry, today announced the appointment of Lori Kahler as President. Kahler will lead the company in the development, promotion and implementation of The RC Insight Group.
Kahler joined The RC Insight Group in 2009. She was the Director of Quality and Regulatory Affairs for Heartlab, LLC (acquired by Agfa-Gevaert) from 2000 to 2005. From 2005 to 2007, she was Global Director of Quality Assurance and Regulatory Affairs of the Cardiovascular Business Unit for the Agfa-Gevaert Group. Prior to her appointment at The RC Insight Group, Kahler was Vice President of Quality Assurance, Regulatory and Clinical Affairs for Ximedica, LLC from 2005 to 2007.
The RC Insight Group provides consulting services in the fields of regulatory affairs, competitive intelligence gathering, clinical trials management, quality systems regulations and strategic planning as they relate to medical product and biotechnology development and related industries.
The RC Insight Group is a collaboration of specialists who understand that our science must serve people. We understand and value how integrated competitive solutions and critical thinking can help our healthcare partners achieve their business goals to improve product performance and healthcare outcomes.
The collaborative member consultants of The RC Insight Group each have a unique blend of experience in efficient and competitive regulatory and clinical strategy development for U.S. and international based clients and projects.
Every stage of your product’s lifecycle presents opportunities to impact performance and regulatory strategy. Incorporating regulatory and clinical expertise of The RC Insight Group early in the product development planning ensures efficient evaluation and implementation of product market pathways that are both compliant and cost effective, while successfully navigating the complex and highly evolving regulatory landscape.
The RC Insight Group provides a broad spectrum of consulting support, from preclinical to commercialization and beyond. Under the leadership of our regulatory affairs experts, our team will work closely with you and regulatory agencies around the world to promote a compliant, high-quality, and efficient application and submission process.
We leverage our collaborative experience with drugs, biologics, and devices (including drug/device combination products) to provide a comprehensive product development strategy, drawing on the scientific rigor and research excellence.
# # #
Read the full story at http://www.prweb.com/releases/2009/12/prweb3374454.htm.
Copyright©2009 Vocus, Inc.
All rights reserved